CLARAVA
Registro de marca em vigor (Madri)
Marca Nominativa depositada no INPI em
03/09/2021 por Verici Dx Plc,
processo nº 501621013, nas classes 05, 10, 42, 44.
Registro em vigor até 03/09/2031.
| Número do processo | 501621013 |
|---|
| Situação | Registro de marca em vigor (Madri) |
|---|
| Apresentação | Nominativa |
|---|
| Natureza | Madri
Produto/Serviço |
|---|
| Data do depósito | 03/09/2021 |
|---|
| Data da concessão | 10/10/2023 |
|---|
| Vigência até | 03/09/2031 |
|---|
| Titular | Verici Dx Plc |
|---|
| CNPJ/CPF do titular | — |
|---|
| UF · País | — · GB |
Classes e especificação
Medical diagnostic blood or biopsy testing reagents and assays for advanced next-generation sequencing science for creating immune profiling of kidney transplant recipients for predicting and identifying risk of graft rejection; medical diagnostic reagents consisting primarily of reagents for use in disease testing and prediction; nucleic acid sequences and chemical reagents for medical purposes.;
Blood test collection kit comprised of blood collection tube and bag, and holder for medical sample tubes, for predicting and identifying the risk of graft injury and graft loss in kidney transplant recipients.;
Development of new technology for others in the field of medical devices and medical diagnostic apparatuses; research, development and consultation related thereto in the field of medical devices and medical diagnostic apparatuses through the use of artificial intelligence; laboratory research in the field of kidney transplant; medical research services; computer software development; providing temporary use of on-line non-downloadable software and software applications using artificial intelligence for medical analysis; none of the foregoing in the fields of business analytics, market intelligence, or business intelligence.;
Medical profile and medical record analysis designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms; medical analysis services for predicting and identifying risk of graft rejection in kidney transplant patients; none of the foregoing in the fields of business analytics, market intelligence, or business intelligence.;